Elisabeth-Tweesteden Ziekenhuis
- Address
- lock Available on a paid plan
Cardiology and Acute Cardiovascular Disease
At Elisabeth-Tweesteden Ziekenhuis in Tilburg, the strongest focus is on urgent heart care, with studies in myocardial infarction, STEMI, and cardiogenic shock. These trials are designed to test new ways to improve survival, reduce complications, and support faster treatment in people with severe heart attacks.
- Evaluating a new treatment approach for acute heart attack care in the pre-hospital setting
- Studying strategies to improve outcomes in cardiogenic shock after acute myocardial infarction
- Testing therapies aimed at lowering inflammation and reducing major cardiovascular events
This research area brings together emergency cardiovascular medicine and prevention, with a clear goal of improving both immediate treatment and longer-term heart health.
Cardiovascular Risk Reduction and Prevention
Another major theme is prevention of future heart problems in people with established cardiovascular disease, elevated lipoprotein(a), or other high-risk conditions. These studies are focused on lowering the chance of serious events such as heart attack, stroke, and urgent revascularization.
- Assessing treatments for people with elevated lp(a) and established cardiovascular disease
- Exploring therapies intended to reduce MACE and improve long-term protection
- Studying inflammation-related approaches to prevent recurrent myocardial infarction
The site’s work in this field reflects a strong interest in reducing cardiovascular risk through new medicines and better preventive care.
Kidney Disease and Hypertension
The site also contributes to research in digestive system diseases and related chronic conditions, including chronic kidney disease with hypertension. These trials are aimed at slowing disease progression and improving overall health in patients living with long-term kidney and blood pressure problems.
- Testing whether new treatment combinations can slow CKD progression
- Evaluating approaches that may better control hypertension in high-risk patients
- Measuring changes in kidney function over time to understand treatment benefit
This area highlights a broader interest in protecting organ function and improving care for patients with overlapping cardiometabolic conditions.
Oncology and Gastrointestinal Cancer
In the field of neoplasms, the research includes studies in diffuse large B-cell lymphoma and advanced gastric cancer with peritoneal dissemination. These trials are investigating whether new treatment combinations can improve survival and offer better disease control than current standard approaches.
- Comparing a new antibody-based treatment strategy with standard immunochemotherapy in DLBCL
- Studying surgery-based treatment approaches for gastric cancer with spread to the peritoneum
- Assessing whether novel cancer therapies can improve outcomes for patients with difficult-to-treat disease
This oncology portfolio shows that Elisabeth-Tweesteden Ziekenhuis is involved in both blood cancer and gastrointestinal cancer research, with attention to treatment effectiveness and patient survival.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 38 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1AstraZeneca AB1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB3trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Elisabeth-Tweesteden Ziekenhuis
lock Showing 1 of 20 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 38 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Oxaliplatin | 3 | Unknown | 2017-09-28 | 2021-03-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.